Diurnal motor variations to repeated doses of Levodopa in Parkinson's disease

Clinical Neuropharmacology

Volumn 23, Issue 1, 2000, Pages 28-33

  Bonuccelli, Ubaldo ^c   Del Dotto, Paolo ^d   Lucetti, Claudio ^d   Petrozzi, Lucia ^d   Bernardini, Silvia ^d   Gambaccini, Gianna ^d   Rossi, Giuseppe ^a   Piccini, Paola ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PISA   (Italy)

^d NONE

Author keywords

Levodopa; Parkinson's disease; Tolerance

Indexed keywords

3 O METHYLDOPA; CARBIDOPA; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; DRUG BLOOD LEVEL; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; TREMOR; WALKING;

ADMINISTRATION, ORAL; ANTIPARKINSON AGENTS; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; TREMOR; TYROSINE; WALKING;

EID: 0033980981     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200001000-00006     Document Type: Article

References (26)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspect. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths, 1982:96-122.
2. Fahn S. Adverse effects of levodopa in Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. Berlin: Springer Verlag, 1989:385-409.
3. Frankel JP, Pirtosek Z, Kempster PA, et al. Diurnal differences in response to oral levodopa. J Neurol Neurosurg Psychiatry 1990;53: 948-50.
4. Melamed E, Bitton V, Zelig O. Episodic total unresponsiveness to single doses of L-dopa in parkinsonian fluctuators: a side effect of long-term L-dopa therapy. Neurology 1986;36:100-3.
5. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-4.
6. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 1987;37:940-4.
7. Luquin MR, Vaamonde J, Obeso JA. Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response. Clin Neuropharmacol 1989;12:46-54.
8. Davis TL, Brughitta G, Baronti F, Mouradian M. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-3.
9. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-6.
10. Gerlach M, Klaunzer N, Przuntek H. Determination of L-Dopa and 3-O-methyldopa in human plasma by extraction using C18 cartridges followed by high-performance liquid chromatographic analysis with electrochemical detection. J Chromatogr 1986;380: 379-85.
11. Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-92.
12. Nutt JG, Carter JH, Woodward WR, Hammerstad JP, Gancher ST. Does tolerance develop to levodopa? Comparison of 2-and 21-H levodopa infusions. Mov Disord 1993;8:139-43.
13. Nutt JC, Carter JH, Woodward WR. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology 1994;44:1617-22.
14. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
15. Sweet RD, Lee JE, Spigel HE, Mc Dowell F. Enhanced response to low doses of levodopa after withdrawal from chronic treatment Neurology 1972;22:520-5.
16. Cedarbaum JM, Silvestri M, Kutt H. Sustained enterai administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990;40:995-7.
17. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-9.
18. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-70.
19. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
20. Piccini P, Del Dotto P, Pardini C, D'Antonio P, Rossi G, Bonuccelli U. Diurnal worsening in Parkinson patients treated with levodopa [in Italian]. Rev Neurol 1991;61:219-24.
21. Grandas F, Obeso JA. Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin Neuropharmacol 1989;12:14-22.
22. Gancher ST, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992;52:504-10.
23. Luquin MR, Laguna J, Herrero MT, Obeso JA. Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys. J Neurol Sci 1993;114:40-44.
24. Rinne UK. New ergot derivatives in the treatment of Parkinson's disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W, eds. Lisuride and other dopamine agonists. New York: Raven Press, 1983:431-42.
25. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 1995;10:668-71.
26. Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-41.